Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity allogeneic HCT versus conventional consolidation in older adults with AML in first remission
NL-OMON39855Phase 3Active, not recruiting
- Sponsor
- EBMT
- Start
- Jan 2010
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine, cyclosporine and mycophenolate mofetil in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by EBMT. Primary endpoint: Leukemia-free survival. Started Jan 2010; status: active, not recruiting.
02
Drugs
fludarabinecyclosporinemycophenolate mofetil
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON39855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39855.